BTIG analyst Mark Massaro reiterated a Buy rating on Guardant Health (GH – Research Report) yesterday and set a price target of $60.00. The ...

As reproductive health access becomes increasingly restricted across the country, expanding Washington’s law that protects ...

This review discusses the current state of multicancer early detection tests, the role of machine learning in their ...

Health associations are urging governments to ensure Canadian patients don't get caught in the crossfire of the ongoing trade ...

Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...

The test will be reimbursed at the price of $1,495 for Medicare patients during the initial nine-month ADLT period starting on April 1.

Guardant Health said the CMS determination confirms that the Shield test meets the criteria for ADLT status, which is reserved for innovative products that provide novel clinical information that ...

Guardant Health ( NASDAQ: GH) traded higher in the morning hours on Tuesday after the company announced that the U.S. Centers ...

The test will be reimbursed at the price of $1,495 for Medicare patients during the initial nine-month ADLT period starting on April 1.

Guardant Health (GH) announced the Centers for Medicare & Medicaid Services CMS has approved Advanced Diagnostic Laboratory Test ADLT ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid ...